Bright Minds Biosciences Inc
DRUG - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$186.38M
Close$
$8.63
54.5% downside
Current Fair Value
54.5% downsideOvervalued by 54.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $186.38 Million |
|---|---|
| Enterprise Value | $-121,708,571.00 |
| Earnings per Share | $-1.78 |
| Beta | 0.09 |
| Outstanding Shares | 9,830,424 |
Return
| Return on Equity | -7.65% |
|---|---|
| Return on Assets | -7.59% |
| Return on Invested Capital | -11.25% |
Valuation & Multiples
| P/E Ratio | -26.55 |
|---|---|
| PEG | 50.05 |
| Price to Sales | - |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.01 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-1.39
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
December 17, 2026
EPS Estimate
$-1.73
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 94.88% |
|---|---|
| Total Invested | $96,191▼ 99.99% |
| Investors Holding | 16▼ 86.00% |
About Bright Minds Biosciences Inc
26 employees
CEO: Ian McDonald
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agoni...